✦ LIBER ✦

Ocrelizumab in multiple sclerosis: risks and benefits – Author's reply

✍ Scribed by Ludwig Kappos; David Leppert; Jeroen Timmermann; Robert Glanzman; Stephen Hauser

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ocrelizumab in multiple sclerosis: risks

✍ Abhijit Chaudhuri 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 86 KB

Mitoxantrone: benefits and risks in mult

✍ V. Martinelli; M. Radaelli; L. Straffi; M. Rodegher; G. Comi 📂 Article 📅 2009 🏛 Springer Milan 🌐 English ⚖ 119 KB

Autologous haematopoietic stem-cell tran

✍ E. Capello; L. Vuolo; F. Gualandi; M. T. Van Lint; L. Roccatagliata; L. Bonzano; 📂 Article 📅 2009 🏛 Springer Milan 🌐 English ⚖ 120 KB

Cyclophosphamide as second-line therapy

✍ Luciano Rinaldi; P. Perini; M. Calabrese; P. Gallo 📂 Article 📅 2009 🏛 Springer Milan 🌐 English ⚖ 137 KB

Balancing the benefits and risks of dise

✍ Per Soelberg Sørensen 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 199 KB

Barrett’s oesophagus in systemic scleros

✍ I. Marie 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 426 KB